• Je něco špatně v tomto záznamu ?

Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells

A. Mazurakova, L. Koklesova, D. Vybohova, M. Samec, E. Kudela, K. Biringer, M. Šudomová, STS. Hassan, M. Kello, D. Büsselberg, O. Golubnitschaja, P. Kubatka

. 2023 ; 14 (-) : 1160068. [pub] 20230406

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010041

Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy. Accumulating studies suggest the crucial role of stem cells in tumour biology, high metastatic activity, and therapy resistance of aggressive breast cancer. Therefore, targeting breast cancer stem cells is a promising treatment approach in secondary and tertiary breast cancer care. To this end, naturally occurring substances demonstrate high potential to target cancer stem cells which, however, require in-depth analysis to identify effective anti-cancer agents for cost-effective breast cancer management. The current article highlights the properties of flavonoids particularly relevant for targeting breast cancer stem cells to mitigate therapy resistance. The proposed approach is conformed with the principles of 3P medicine by applying predictive diagnostics, patient stratification and treatments tailored to the individualised patient profile. Expected impacts are very high, namely, to overcome limitations of reactive medical services improving individual outcomes and the healthcare economy in breast cancer management. Relevant clinical applications are exemplified in the paper.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010041
003      
CZ-PrNML
005      
20230721095341.0
007      
ta
008      
230707s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2023.1160068 $2 doi
035    __
$a (PubMed)37089930
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mazurakova, Alena $u Department of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
245    10
$a Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells / $c A. Mazurakova, L. Koklesova, D. Vybohova, M. Samec, E. Kudela, K. Biringer, M. Šudomová, STS. Hassan, M. Kello, D. Büsselberg, O. Golubnitschaja, P. Kubatka
520    9_
$a Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy. Accumulating studies suggest the crucial role of stem cells in tumour biology, high metastatic activity, and therapy resistance of aggressive breast cancer. Therefore, targeting breast cancer stem cells is a promising treatment approach in secondary and tertiary breast cancer care. To this end, naturally occurring substances demonstrate high potential to target cancer stem cells which, however, require in-depth analysis to identify effective anti-cancer agents for cost-effective breast cancer management. The current article highlights the properties of flavonoids particularly relevant for targeting breast cancer stem cells to mitigate therapy resistance. The proposed approach is conformed with the principles of 3P medicine by applying predictive diagnostics, patient stratification and treatments tailored to the individualised patient profile. Expected impacts are very high, namely, to overcome limitations of reactive medical services improving individual outcomes and the healthcare economy in breast cancer management. Relevant clinical applications are exemplified in the paper.
590    __
$a NEINDEXOVÁNO
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Koklesova, Lenka $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Vybohova, Desanka $u Department of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Samec, Marek $u Department of Pathological Physiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Kudela, Erik $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Biringer, Kamil $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Šudomová, Miroslava $u Museum of Literature in Moravia, Rajhrad, Czechia
700    1_
$a Hassan, Sherif T S $u Department of Applied Ecology, Faculty of Environmental Sciences, Czech University of Life Sciences Prague, Prague, Czechia
700    1_
$a Kello, Martin $u Department of Pharmacology, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia
700    1_
$a Büsselberg, Dietrich $u Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Qatar Foundation, Doha, Qatar
700    1_
$a Golubnitschaja, Olga $u Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
700    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 14, č. - (2023), s. 1160068
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37089930 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095334 $b ABA008
999    __
$a ok $b bmc $g 1958613 $s 1196305
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1160068 $e 20230406 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20230707

Najít záznam

Citační ukazatele

Možnosti archivace